Closely-held Ripple Therapeutics, a recent spinout from Interface Biologics, is pursuing a $25-million series A financing to complete a Phase 2 trial of IBE-814 IVT, a dexamethasone prodrug intravitreal implant, and...

Stereotaxis’ (NYSE American: STXS) launch in June 2019 of a next generation surgical robotic system, Genesis RMN, solidifies its commitment to innovation and collaboration as a stepping stone to improve patient care...

Closely-held pharmacogenetics company, Inagene Diagnostics, aims to replace the “trial-and-error” approach to pain management with a comprehensive genetic test that helps physicians provide personalized pain management...

Closely-held Squarex will be seeking an end-of-Phase 2 meeting with the FDA in the first quarter of 2020 as a steppingstone for pivotal testing of its SQX770 topical treatment for the prevention of recurrent cold sores...

With FDA approval in October of its VMS+ 3.0 system, which turns 2D echocardiograms into MRI equivalent 3D images, Ventripoint Diagnostics (TSXV:VPT, OTCQB:VPTDF) is gearing up for a major sales and marketing program in...

Closely-held Lobo Genetics is taking its cannabis genetic profile testing to the next level. “We started with genetic tests and genetic profiling and now we are complementing that by helping guide consumers to the right...

Closely-held Soricimed Biopharma has developed a first-in-class platform of synthetic peptides whose various targets include an “oncochannel” implicated in the development and progression of many forms of cancer.

OncoSec Medical (NASDAQ:ONCS) is developing its TAVO drug candidate to enhance local delivery and uptake of DNA-based interleukin-12 (IL-12) directly into solid tumors to reverse patients’ resistance to checkpoint...